1. sr9009 is an investigational selective androgen receptor modulator (sarm) developed by the scripps research institute. sr9009 can help to reduce body fat without any complicated diet plans or intense workouts. it even helps with muscle development.
2. a drug known as sr9009, which is currently under increases the level of metabolic activity in skeletal muscles. it also effects can be obtained, the reversal of obesity, metabolic syndrome, and perhaps type-ii diabetes patient might be welcome it.some studies showing , the sr9009 drug may offer new therapies for obesity and its companions, metabolic syndrome and diabetes.
3. another area in which sr9009 or a similar drug may confer substantial benefit is to offset the loss of general muscle conditioning which occurs as a side effect of reduced activity caused by illness and/or aging.
4. people most likely to enjoy these benefits include those suffering from severe arthritis, congestive heart failure, chronic obstructive pulmonary disease (copd), and other conditions that restrict the ability to exercise.
|Ostarine,MK-2866, Enobosarm||Enobosarm (Ostarine, MK-2866, GTx-024) - affects both muscle and bone, intended mainly for osteoporosis but also general treatment for andropause and reversing muscle sarcopenia in the elderly and for cachexia in cancer patients.|
|LGD-4033||pharmacological profile similar to that of enobosarm, Ostarine,MK-2866|
|MK-677, Ibutamoren, a hormone secretagogue||a owth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly.|
|Andarine (S-4)||partial agonist, intended mainly for treatment of benign prostatic hypertrophy.|
|GW-501516||It had been investigated as a potential treatment for obesity, diabetes, dyslipidemia and cardiovascular disease.|
|RAD140||to help reduce the androgenic side effects that can be potentially caused by the same on the prostate.|
|SR9009||to increased metabolic activity in skeletal muscle in both culture and in mice.|